Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of midapril hydrochloride for hypertension with coronary heart disease
ChiCTR2400092991Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of the University of South China
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of imidapril in hypertension (HTN) and coronary arteriosclerosis, sponsored by The First Affiliated Hospital of the University of South China. Primary endpoint: Antihypertensive efficiency. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
imidapril
03
Conditions
hypertension (HTN)coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2400092991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092991.